We combined a fluorescent imaging agent and the novel tumor metastasis targeting peptide TMTP1, the potential receptor of which, XPNPEP2, was significantly upregulated in cervical cancer tissues, especially in micrometastases, thus providing the possibility of the wide use of ITM for clinical imaging of situ and cervical cancer metastasis. Here, XPNPEP2 is linked to cervical carcinoma.